Navamedic aktie (NAVA) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Spartips: Skattefritt sparande i ISK/KF under 2025 – tips på populära sparformer

Pressmeddelanden från Navamedic

 Bevaka pressreleaser
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Cision • 15 Nov 13:00

Navamedic ASA: Mandatory notice of trade

Navamedic ASA: Mandatory notice of trade

Cision • 06 Nov 13:52

Navamedic launches Eroxon[®] in Finland

Oslo, 6 November 2024 – Building on the successful product launch of Eroxon[®] in Norway and Sweden earlier this year, Navamedic ASA (OSE: N...

Cision • 06 Nov 09:10

Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business

Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quali...

Cision • 31 Oct 07:00

Navamedic ASA: Invitation to 2024 3rd quarter presentation

Navamedic ASA: Invitation to 2024 3rd quarter presentation

Cision • 28 Oct 09:08

Navamedic wins joint Nordic antibiotics tender

Oslo, 07 October 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and p...

Cision • 07 Oct 13:56

Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to ...

Cision • 12 Sep 12:00

Navamedic ASA – Mandatory notification of trade by primary insider

Navamedic ASA – Mandatory notification of trade by primary insider

Cision • 09 Sep 16:47

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Cision • 09 Sep 16:03

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality produ...

Cision • 16 Aug 07:00

Navamedic ASA: Invitation to 2024 2nd quarter presentation

Navamedic ASA: Invitation to 2024 2nd quarter presentation

Cision • 12 Aug 10:00

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe

Cision • 24 Jun 16:19

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Minutes of Annual General Meeting

Cision • 04 Jun 10:18

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Cision • 16 May 09:00

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA: Notice of Annual General Meeting

Cision • 14 May 14:10

Första behandlingen mot erektionsproblem utan recept lanseras på svenska apotek

Stockholm den 6 maj 2024 För första gången finns en behandling mot erektionsproblem tillgänglig utan recept på svenska apotek.

Cision • 06 May 11:00

Navamedic ASA: Broad launch for Eroxon® in Sweden today

Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharma...

Cision • 06 May 11:00

Navamedic ASA: Annual Report 2023

Navamedic ASA: Annual Report 2023

Cision • 30 Apr 17:45

Navamedic Q1 2024: Successful product launch and steady operational progress

Navamedic Q1 2024: Successful product launch and steady operational progress

Cision • 30 Apr 07:00

Navamedic ASA: Invitation to 2024 1st quarter presentation

Navamedic ASA: Invitation to 2024 1st quarter presentation

Cision • 23 Apr 14:30

Navamedic ASA – Registration of share capital increase

Navamedic ASA – Registration of share capital increase

Cision • 02 Apr 14:38

Navamedic welcomes new shareholders

Navamedic welcomes new shareholders

Cision • 13 Mar 10:31

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

  Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals a...

Cision • 15 Feb 08:00

Navamedic ASA: Invitation to 2023 4th quarter presentation

Navamedic ASA: Invitation to 2023 4th quarter presentation

Cision • 13 Feb 08:00

Navamedic ASA: Renewed contract signed with Vitaflo International Limited

Oslo, 21 December 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and ...

Cision • 21 Dec 2023 17:20

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe

Cision • 13 Dec 2023 18:51

Navamedic ASA: Record high quarter with above 50 percent growth

Oslo, 1 November 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and p...

Cision • 01 Nov 2023 08:00

Navamedic ASA: Invitation to 2023 3rd quarter presentation

Navamedic ASA: Invitation to 2023 3rd quarter presentation

Cision • 27 Oct 2023 11:13

Navamedic ASA – Mandatory notification of trade by primary insider

Navamedic ASA – Mandatory notification of trade by primary insider

Cision • 18 Aug 2023 12:31

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

Cision • 18 Aug 2023 11:56

Navamedic ASA: Significant growth across the business

Oslo, 11 August 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and ph...

Cision • 11 Aug 2023 08:00

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Cision • 07 Aug 2023 12:24

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Minutes of Annual General Meeting

Cision • 01 Jun 2023 11:35

Updated recommendation by the nomination committee of Navamedic ASA

Updated recommendation by the nomination committee of Navamedic ASA

Cision • 31 May 2023 14:16

Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 26 May 2023 08:00

Navamedic offentliggör slutligt utfall i erbjudandet till aktieägarna och innehavarna av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 26 May 2023 08:00

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Oslo, 26 May 2023 – Following the closing of the acceptance period in the previously announced public offer, Navamedic ASA (OSE: NAVA), a No...

Cision • 26 May 2023 08:00

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 17 May 2023 17:45

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 17 May 2023 17:45

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 12 May 2023 15:00

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 12 May 2023 15:00

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA: Notice of Annual General Meeting

Cision • 11 May 2023 12:00

Navamedic ASA Q1 2023: Another strong quarter

Oslo, 11 May 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharm...

Cision • 11 May 2023 08:00

Navamedic höjer vederlaget till 8,50 kronor kontant per aktie i sitt ovillkorade offentliga uppköpserbjudande och kallar till extra bolagsstämma i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 10 May 2023 09:00

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 10 May 2023 09:00

Navamedic ASA: Invitation to 2023 1st quarter presentation

Navamedic ASA: Invitation to 2023 1st quarter presentation

Cision • 08 May 2023 10:41

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 28 Apr 2023 15:10

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 28 Apr 2023 15:10

Navamedic ASA: Annual Report for 2022

Oslo, 28 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pha...

Cision • 28 Apr 2023 13:20

Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 26 Apr 2023 12:20

Navamedic höjer vederlaget till 0,60 kronor kontant per teckningsoption av serie TO 1 i det ovillkorade erbjudandet till teckningsoptionsinnehavarna i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 26 Apr 2023 12:20

Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 25 Apr 2023 22:10

Navamedic ASA utökar sitt erbjudande till att omfatta teckningsoptioner av serie TO 1 emitterade av Sensidose Aktiebolag till ett pris om 0,38 kronor kontant per teckningsoption av serie TO 1

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 25 Apr 2023 22:10

Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag

Press release 24 April 2023 Navamedic ASA published a press release on 24 April 2023 21:30 p.

Cision • 24 Apr 2023 22:45

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende dess kontanterbjudande till aktieägarna i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 24 Apr 2023 21:30

Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 24 Apr 2023 21:30

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Oslo, 22 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, ...

Cision • 22 Apr 2023 13:10

Navamedic completes the offer, has entered into agreements to acquire approximately 56.7 per cent of the shares in Sensidose and increases the consideration to SEK 8 in cash per share

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 22 Apr 2023 13:00

Navamedic fullföljer erbjudandet, har ingått avtal om förvärv av cirka 56,7 procent av aktierna i Sensidose och höjer vederlaget till 8 kronor kontant per aktie i Sensidose

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 22 Apr 2023 13:00

Navamedic ASA lämnar ett enhälligt rekommenderat kontanterbjudande om 6,27 kronor per aktie till aktieägarna i Sensidose Aktiebolag

Detta pressmeddelande utgör inte ett erbjudande, vare sig direkt eller indirekt, i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Singapo...

Cision • 29 Mar 2023 07:30

Navamedic ASA announces a unanimously recommended cash offer of SEK 6.27 per share to the shareholders of Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Afr...

Cision • 29 Mar 2023 07:30

Navamedic ASA: Q4 2022 financial results

Oslo, 16 February 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and ...

Cision • 16 Feb 2023 08:00

Navamedic ASA: Invitation to 2022 4th quarter presentation

Navamedic ASA: Invitation to 2022 4th quarter presentation

Cision • 13 Feb 2023 09:00

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region

Oslo, 23 November 2022 - Navamedic has signed an agreement with its partner InfoRLife SA (subsidiary of ACS Dobfar S.

Cision • 23 Nov 2022 10:05

Navamedic ASA: Q3 2022 financial results

Oslo, 1 November 2022 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and p...

Cision • 01 Nov 2022 08:00

Navamedic ASA: Invitation to 2022 third quarter presentation

Navamedic ASA: Invitation to 2022 third quarter presentation

Cision • 25 Oct 2022 15:41

Navamedic ASA launches ForlaxGO® - an innovative on-the-go product for the treatment of constipation

Oslo, 20 October 2022 – Navamedic ASA (OSE: NAVA) today announces the launch of ForlaxGO® across pharmacies in Norway, Sweden, Finland and D...

Cision • 20 Oct 2022 08:40

Navamedic ASA: Q2 and first half 2022 financial results

Oslo, 12 August 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and ph...

Cision • 12 Aug 2022 08:00

Navamedic ASA: Invitation to 2022 second quarter presentation

Navamedic ASA: Invitation to 2022 second quarter presentation

Cision • 09 Aug 2022 14:22

Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Cision • 04 Aug 2022 14:09

Navamedic ASA: Trading Update

Oslo, 4 July 2022 – Navamedic ASA (OSE: NAVA) today announces a trading update based on updated estimated revenue growth in excess of 30% or...

Cision • 04 Jul 2022 19:23

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Minutes of Annual General Meeting

Cision • 02 Jun 2022 13:48

Navamedic ASA completes acquisition of Impolin AB and issues consideration shares

Navamedic ASA completes acquisition of Impolin AB and issues consideration shares

Cision • 01 Jun 2022 16:07

Navamedic ASA: Q1 2022 financial results

Navamedic ASA: Q1 2022 financial results

Cision • 10 May 2022 08:00

Navamedic ASA acquires Impolin AB and bolsters its product portfolio

Navamedic ASA acquires Impolin AB and bolsters its product portfolio

Cision • 05 May 2022 11:35

Navamedic: Annual report 2021

Navamedic: Annual report 2021

Cision • 29 Apr 2022 08:00

Navamedic ASA: Q4 2021 financial results

Oslo, 17 February 2022 - Navamedic ASA (OSE: NAVA) grew revenues by 63% in the fourth quarter of 2021 compared to the same quarter last year...

Cision • 17 Feb 2022 08:00

Navamedic ASA launches SmectaGO[®] - an innovative on-the-go product for treatment of diarrhea

Oslo, 16 February 2022 – Navamedic ASA (OSE: NAVA) today announces the launch of SmectaGO[®] for sale through pharmacies in Norway, Sweden, ...

Cision • 16 Feb 2022 16:40

Navamedic ASA: Invitation to 2021 Fourth quarter presentation

Navamedic ASA: Invitation to 2021 Fourth quarter presentation

Cision • 14 Feb 2022 14:30

Navamedic ASA: Trading Update

Oslo, 23 December 2021 – Navamedic ASA (OSE: NAVA) today announces a trading update based on updated revenue growth expectation for the full...

Cision • 23 Dec 2021 13:34

Navamedic ASA has entered into a market making agreement with Norne Securities AS

Navamedic ASA has entered into a market making agreement with Norne Securities AS

Cision • 11 Nov 2021 08:00

Navamedic ASA: Q3 2021 financial results

Oslo, 4 November 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 12% in the third quarter of 2021 compared to the same quarter last year.

Cision • 04 Nov 2021 08:00

Navamedic ASA: Invitation to 2021 Third quarter presentation

Navamedic ASA: Invitation to 2021 Third quarter presentation

Cision • 28 Oct 2021 10:58

Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Oslo, 12 October 2021 – Navamedic ASA (OSE: NAVA) today announces it has exercised a five-year extension of its exclusive distribution right...

Cision • 12 Oct 2021 09:00

Webbinarium: NYA NATIONELLA RIKTLINJER OBESITAS

- Vad innebär det i praktiken? Socialstyrelsens riktlinjer för Obesitasvård presenteras i remissversion i början av nästa år och detta vill ...

Cision • 04 Oct 2021 13:26

Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Oslo, 7 September 2021 – Navamedic ASA (OSE: NAVA) receives approval for conditional reimbursement for Mysimba® in Finland from 1 November 2...

Cision • 07 Sep 2021 15:50

Navamedic ASA: Q2 and first half 2021 financial results

Oslo, 13 August 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 56.

Cision • 13 Aug 2021 08:00

Navamedic ASA: Invitation to 2021 Second quarter presentation

Navamedic ASA: Invitation to 2021 Second quarter presentation

Cision • 10 Aug 2021 16:11

Navamedic ASA: Launch of new products strengthen the category of Medical Nutrition

Oslo June 1[th], 2021 – Navamedic ASA (“Navamedic”, OSE: NAVA) announces the launch of new products in the Nordics.

Cision • 01 Jun 2021 09:51

Obesity patient support program launched in Norway

Today Navamedic launches MyControl Support in Norway, a free-of-charge patient support program in collaboration with Observia, following a s...

Cision • 20 May 2021 11:53

Navamedic ASA: Notice of Annual General Meeting

Navamedic ASA: Notice of Annual General Meeting

Cision • 12 May 2021 11:00

Navamedic ASA: Q1 2021 financial

Oslo, 11 May 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 5.

Cision • 11 May 2021 08:00

Navamedic ASA: Invitation to 2021 first quarter presentation

Navamedic ASA: Invitation to 2021 first quarter presentation

Cision • 06 May 2021 13:31

Navamedic ASA: Annual report 2020

Navamedic ASA: Annual report 2020

Cision • 30 Apr 2021 12:37